Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford pain researchers are playing a major role in a new multi-million pound research programme launched by a consortium of funders, including UKRI, Versus Arthritis, Eli Lilly and the Medical Research Foundation.

View of a woman's back that she is clutching in pain
This is a journey. A lot of fantastic research has been done in the past, but we haven't cracked the problem yet, and we need to develop new ways to go forward. This can be achieved through patient partners and scientists working collectively, and effectively, to move research forward. We hope that this can deliver the best outcomes for patients with chronic pain. - David Walsh, Director of the Advanced Pain Discovery Platform

The Advanced Pain Discovery Platform (APDP) is a UK-based network of scientists, clinicians and patients who are coming together to try and deliver new breakthroughs in understanding human pain.

Chronic pain is one of the greatest unmet needs in healthcare. It is the leading global cause of disability and carries an enormous socioeconomic cost in the UK and worldwide. But progress in delivering new treatments has been difficult and slow.

The APDP represents the largest ever coordinated programme of pain research in the UK, and comprises experts in clinical and neurobiological aspects of pain, sociologists, psychologists, and data scientists, and spans research and healthcare institutions across the UK and beyond. The APDP has a particularly strong involvement of people with lived experience of chronic pain.

Read the full story on the Nuffield Department of Clinical Neurosciences website. 

Similar stories

Oxford spinout Optellum secures $14m funding to advance pioneering AI-powered lung cancer diagnosis technology

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

New study shows higher rate of fractures in people with intellectual disability

In the most comprehensive study of its kind, researchers at the University of Oxford and Oxford Health NHS Foundation Trust found a substantially higher rate of fractures in people with intellectual disability compared with people of the same age and gender without an intellectual disability.

New evidence for how our brains handle surprise

A new study from the Bruno Group is challenging our perceptions of how the different regions of the cerebral cortex function. A group of ‘quiet’ cells in the somatosensory cortex that rarely respond to touch have been found to react mainly to surprising circumstances. The results suggest their function is not necessarily driven by touch, but may indicate an important and previously unidentified role across all the major cortices.

Language learning difficulties in children linked to brain differences

A new study using MRI has revealed structural brain changes in children with developmental language disorder (DLD), a common but under-recognised difficulty in language learning. Children with DLD aged 10-15 showed reduced levels of myelin in areas of the brain associated with speaking and listening to others, and areas involved in learning new skills. This finding is a significant advance in our understanding of DLD and these brain differences may explain the poorer language outcomes in this group.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.